Physician profile
Dawn Rozar
NPI 1306594262
$7,487.72
in general payments reported to CMS, 2019-2025
43 companies · $2,980 in 2025
The $2,980 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,772 · 2024: $2,736 · 2025: $2,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,487.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,007.48 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $727.11 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $716.67 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $635.47 | 2023-2025 | |
| Abbvie INC. | $381.22 | 2023-2025 | |
| Astellas Pharma US INC | $346.91 | 2023-2025 | Veozah |
| Amgen INC. | $333.92 | 2023-2025 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $319.47 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Lilly USA, LLC | $299.43 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Noven Therapeutics, LLC | $289.67 | 2023-2025 | Xelstrym |
| Sumitomo Pharma America, INC. | $221.36 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $187.14 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $184.82 | 2023-2024 | Xarelto |
| Vanda Pharmaceuticals INC. | $161.97 | 2023-2025 | Fanapt, Hetlioz |
| Merck Sharp & Dohme LLC | $156.32 | 2023-2025 | Verquvo, Gardasil 9, Capvaxive |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $147.55 | 2023-2025 | |
| Shield Therapeutics INC | $145.22 | 2023-2025 | Accrufer |
| Lundbeck LLC | $119.50 | 2025 | Rexulti |
| Ardelyx, INC. | $88.62 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $87.92 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $87.50 | 2023-2025 | Nuzyra |
| Teva Pharmaceuticals USA, INC. | $84.13 | 2023-2025 | Austedo Xr, Austedo, Ajovy |
| Exact Sciences Corporation | $83.51 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $78.37 | 2023-2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.62 | 2024-2025 | Caplyta |
| Scilex Pharmaceuticals INC. | $66.98 | 2023 | Ztlido |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.35 | 2024-2025 | Jardiance, Synjardy |
| Dexcom, INC. | $42.26 | 2023-2024 | Dexcom G6 Transmitter |
| Collegium Pharmaceutical, INC. | $39.05 | 2025 | Belbuca |
| Sanofi-Aventis U.S. LLC | $37.81 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $36.86 | 2023-2025 | Gvoke Hypopen |
| Indivior INC. | $35.90 | 2024-2025 | Sublocade |
| Tolmar, INC. | $28.61 | 2023-2024 | |
| Eisai INC. | $24.55 | 2025 | |
| Ironwood Pharmaceuticals, INC | $21.93 | 2023 | Linzess |
| Ucb, INC. | $21.67 | 2023 | Nayzilam |
| Smith+Nephew, INC. | $20.70 | 2024 | Collagenase Santyl |
| Viatris Specialty LLC | $19.31 | 2025 | Yupelri |
| Esperion Therapeutics, INC. | $17.04 | 2025 | Nexletol |
| Cequr Corporation | $16.52 | 2025 | Cequr Simplicity |
| Idorsia Pharmaceuticals US INC | $14.90 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $14.61 | 2025 | Zoryve |
| Impel Pharmaceuticals INC. | $12.77 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Rozar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.